Search results
Results from the WOW.Com Content Network
Urine contained 2.1 μg/L for the metabolite, and a detection below level of quantification for MDMB-4en-PINACA itself. [ 23 ] Adulterated Cannabis products in Europe that have been laced with MDMB-4en-PINACA have contained 0.3 to 4.6 μg/mg in seized flower samples and 1.7 to 7.2 μg/mg in hash/or other extract samples.
AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the ...
Download as PDF; Printable version; In other projects ... is a synthetic cannabinoid compound which has been sold as a designer drug. [4 ... It is a potent CB 1 ...
4F-MDMB-BINACA (also known as MDMB-4F-BINACA, [2] 4F-MDMB-BUTINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family. [3] It should not be confused with the amantadine analogue 4F-ABINACA. It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018.
AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA [3]) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with K i values of 10.04 nM at CB 1 and 0.786 nM at CB 2 and EC 50 values of 0.5433 nM at CB 1 and 0.1278 nM at CB 2, [4] and has been sold online as a designer drug.
5F-CUMYL-PINACA (also known as SGT-25 and sometimes sold in e-cigarette form as C-Liquid) [1] is an indazole-3-carboxamide based synthetic cannabinoid. [2] 5F-CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with the original patent claiming approximately 4x selectivity for CB 1, having an EC 50 of <0.1 nM for human CB 1 receptors and 0.37 nM for human CB 2 receptors. [3]
O-1602 is a synthetic compound most closely related to abnormal cannabidiol, and more distantly related in structure to cannabinoid drugs such as THC.O-1602 does not bind to the classical cannabinoid receptors CB 1 or CB 2 with any significant affinity, but instead is an agonist at several other receptors which appear to be related to the cannabinoid receptors, particularly GPR18 and GPR55.
Compared to THC, which is a partial agonist at CB 1 receptors, JWH-018, and many synthetic cannabinoids, are full agonists. JWH-018 may cause intense anxiety, agitation, and in rare cases, has been assumed to have been the cause of seizures and convulsions. JWH-018 and analogs of it may present serious dangers to the user when used to excess. [22]